Scientists pinpoint ideal sedative dose for sleep apnea scopes
NCT ID NCT06333145
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This trial aims to find the 90% effective dose of remimazolam, a sedative, for drug-induced sleep endoscopy in adults. The study includes people of different body sizes to see if the ideal dose varies. Participants will receive remimazolam and be monitored for sedation success and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- remimazolam
- What this could lead to
- If successful, this could help doctors use the right dose of remimazolam for sedation during sleep endoscopy, improving safety and effectiveness.
- What could go wrong
- This is a small, early-phase trial focused on dosing, not on treating a disease. Results may not apply to all patients or settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EFFECT OF DRUG are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tongji Hospital
Wuhan, Hubei, 430000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Asthma drug may boost some athletes – study investigates
- New sedative could keep ICU patients calmer on ventilators
- Which sedative works best for ventilator patients? new trial aims to find out
- Small study pinpoints ideal sedation dose for colonoscopy
- Which spinal drug gets you home faster after anal surgery?
- New drug combo shows promise for tough head and neck cancers